Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 549 Carcinoma, Non-Small-Cell Lung 509 Prostatic Neoplasms 333 Colorectal Neoplasms 270 Multiple Myeloma 266 Neoplasms 262 Leukemia, Myeloid, Acute 221 Squamous Cell Carcinoma of Head and Neck 214 Lung Neoplasms 207 Neoplasm Metastasis 203 Carcinoma, Hepatocellular 197 Melanoma 172 Triple Negative Breast Neoplasms 171 Pancreatic Neoplasms 170 Recurrence 152 Ovarian Neoplasms 149 Lymphoma 139 Brain Neoplasms 133 Glioblastoma 132 Sarcoma 130 Carcinoma, Renal Cell 126 Leukemia, Lymphocytic, Chronic, B-Cell 125 Head and Neck Neoplasms 124 Stomach Neoplasms 122 Lymphoma, Large B-Cell, Diffuse 122 Rectal Neoplasms 107 Precursor Cell Lymphoblastic Leukemia-Lymphoma 105 Myelodysplastic Syndromes 102 Uterine Cervical Neoplasms 100 Urinary Bladder Neoplasms 100

Interventions

atezolizumab 1 Radiotherapy 1 Radiosurgery 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × HCC × 1 year × Clear all

NCT06823375 2026-03-04

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Chinese University of Hong Kong

Phase 2 Recruiting

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡